Monitor FDA acceptance decision in Q4 2026 — if the sNDA is accepted with Priority Review, the target action date would be approximately six months later. Approval would open a new indication for XPOVIO, but the binary risk of non-acceptance or FDA disagreement on the surrogate endpoint remains high given the company's $42M market cap and going concern warning.
Price Chart
Executive Summary
Karyopharm announced submission of an sNDA to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis, based on Phase 3 SENTRY trial data showing a promising overall survival signal. Priority Review was requested, which could yield a six-month review cycle. FDA acceptance and review timeline decisions are expected in Q4 2026.
Key Facts
- sNDA submitted for XPOVIO (selinexor) + ruxolitinib in myelofibrosis under Accelerated Approval pathway
- Priority Review requested; if granted, review period would be approximately six months
- FDA decision on sNDA filing acceptance and review timelines expected in Q4 2026
- Submission based on Phase 3 SENTRY trial data with a positive benefit-risk profile and overall survival signal
- Accelerated Approval requires FDA agreement that SVR35 is a reasonably likely surrogate endpoint for overall survival
- Company plans to use long-term overall survival data from SENTRY to support conversion to traditional approval
Financial Impact
No specific financial figures provided; potential expansion of XPOVIO addressable market into myelofibrosis if approved. Company has going concern risk noted in forward-looking statements.
Risk Factors
- FDA may not accept the sNDA or may deny Priority Review
- FDA may not agree that SVR35 is a reasonably likely surrogate endpoint for overall survival
- Company has expressed substantial doubt about its ability to continue as a going concern
- Long-term overall survival data from SENTRY may not verify clinical benefit, preventing conversion to traditional approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-375495 |
| Document: 0001193125-26-375495-index-headers.html | 0001193125-26-375495 |
| Document: 0001193125-26-375495-index.html | 0001193125-26-375495 |
| Document: 0001193125-26-375495.txt | 0001193125-26-375495 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $1.61 $1.88 | ▼ −16.77% | ▼ −16.99% | $0.8050 (+50.00%) |
Aug 31, 2026 4w ago | 8-K | $2.06 $1.72 | ▼ −16.50% | ▼ −16.36% | $0.8050 (−60.92%) |
Aug 13, 2026 7w ago | 8-K | $1.99 $1.82 | ▲ +8.54% | ▲ +6.58% | $0.8050 (+59.55%) |
Aug 10, 2026 7w ago | Press Release | $1.96 $1.81 | ▼ −7.65% | ▼ −7.61% | $0.8050 (−58.93%) |
Jul 31, 2026 9w ago | 8-K | $1.92 $2.12 | ▲ +10.42% | ▲ +6.91% | $0.8050 (−58.07%) |
Jul 17, 2026 10w ago | 8-K | $7.47 $7.41 | ▼ −0.80% | ▼ −0.38% | $0.8050 (−89.22%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▼ −25.63% | ▼ −24.01% | $0.8050 (+88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access